Overview of Dr. Falchi
Dr. Lorenzo Falchi is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from University of Perugia Faculty of Medicine and has been in practice since 2005. He also speaks multiple languages, including Italian. He specializes in hematologic oncology and is experienced in non-hodgkin lymphoma and immunotherapy.
Office
530 East 74th Street
New York, NY 10021
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2015 - 2019
Yale-New Haven Medical CenterResidency, Internal Medicine, 2013 - 2015
University of Texas M.D. Anderson Cancer CenterFellowship, Leukemia , 2012 - 2013- University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, 2011 - 2012
University of PerugiaSpecialist, Cum Laude, 2005 - 2009
University of Perugia Faculty of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2022 - Present
NY State Medical License 2016 - 2026
NJ State Medical License 2019 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- ECFMGECFMG Certificate
Awards, Honors, & Recognition
- Future Leaders in Hematology Celgene, 2013
Clinical Trials
- A Study of Mosunetuzumab in People With Follicular Lymphoma Start of enrollment: 2022 May 27
Publications & Presentations
PubMed
- Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2024-12-11 - Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for gl...Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson
Haematologica. 2024-11-28 - 1 citationsZanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.Anita Kumar, Jacob D Soumerai, Jeremy S Abramson, Jeffrey A Barnes, Philip C Caron
Blood. 2024-10-22
Press Mentions
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients with Diffuse Large B-cell Lymphoma (DLBCL)December 9th, 2024- Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses as Monotherapy and Combination Treatment in Patients with Diffuse Large B-cell LymphomaDecember 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)December 8th, 2024
- Join now to see all
Committees
- Member, Society for immunotherapy of cancer - Early Career Scientists 2016 - Present
Professional Memberships
- Member
- Member
- Member
Other Languages
- Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
